To evaluate the treatment benefits of immune checkpoint inhibitors for NSCLC patients with uncommon EGFR mutations, we reported an NSCLC patient with uncommon EGFR mutation who benefited from immunotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.